Pasithea Historical Income Statement

KTTA Stock  USD 2.58  0.08  3.01%   
Historical analysis of Pasithea Therapeutics income statement accounts such as Total Operating Expenses of 9.8 M can show how well Pasithea Therapeutics Corp performed in making a profits. Evaluating Pasithea Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Pasithea Therapeutics's future profits or losses.
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Pasithea Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Pasithea Therapeutics is a good buy for the upcoming year.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Pasithea Therapeutics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

About Pasithea Income Statement Analysis

Pasithea Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Pasithea Therapeutics shareholders. The income statement also shows Pasithea investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Pasithea Therapeutics Income Statement Chart

At present, Pasithea Therapeutics' Depreciation And Amortization is projected to increase significantly based on the last few years of reporting. The current year's Interest Expense is expected to grow to 223.66, whereas Other Operating Expenses is forecasted to decline to about 9.9 M.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Pasithea Therapeutics. It is also known as Pasithea Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Income Before Tax

Income Before Tax which can also be referred as pre-tax income is reported on Pasithea Therapeutics income statement and is an important metric when analyzing Pasithea Therapeutics profitability. Accounting techniques because taxes can be complex, and not perfectly consistent from one company to company, an analyst may use pre-tax income as a more stable measure of profitability.

Net Income Applicable To Common Shares

The net income that remains after preferred dividends have been deducted, available to common shareholders.
Most accounts from Pasithea Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Pasithea Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Pasithea Therapeutics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
At present, Pasithea Therapeutics' Depreciation And Amortization is projected to increase significantly based on the last few years of reporting. The current year's Interest Expense is expected to grow to 223.66, whereas Other Operating Expenses is forecasted to decline to about 9.9 M.
 2010 2022 2023 2024 (projected)
Reconciled Depreciation1.4K32.4K517.7K543.5K
Cost Of Revenue17.3K113.2K648.5K680.9K

Pasithea Therapeutics income statement Correlations

0.63-0.73-0.78-0.770.63-0.760.12-0.791.01.01.00.7-0.94-0.820.980.990.94
0.63-0.98-0.96-0.971.0-0.970.49-0.960.690.690.690.98-0.39-0.930.760.720.72
-0.73-0.981.01.0-0.981.0-0.480.99-0.79-0.79-0.79-0.970.50.98-0.85-0.81-0.76
-0.78-0.961.01.0-0.960.99-0.480.99-0.83-0.83-0.83-0.960.570.98-0.88-0.85-0.8
-0.77-0.971.01.0-0.970.99-0.490.99-0.82-0.82-0.82-0.960.550.98-0.87-0.84-0.79
0.631.0-0.98-0.96-0.97-0.970.49-0.960.690.690.690.98-0.39-0.930.760.720.72
-0.76-0.971.00.990.99-0.97-0.41.0-0.81-0.81-0.81-0.980.520.99-0.86-0.83-0.78
0.120.49-0.48-0.48-0.490.49-0.4-0.390.20.20.20.3-0.08-0.310.230.210.17
-0.79-0.960.990.990.99-0.961.0-0.39-0.83-0.83-0.83-0.970.560.99-0.89-0.86-0.8
1.00.69-0.79-0.83-0.820.69-0.810.2-0.831.01.00.74-0.92-0.850.991.00.95
1.00.69-0.79-0.83-0.820.69-0.810.2-0.831.01.00.75-0.92-0.850.991.00.95
1.00.69-0.79-0.83-0.820.69-0.810.2-0.831.01.00.75-0.92-0.850.991.00.95
0.70.98-0.97-0.96-0.960.98-0.980.3-0.970.740.750.75-0.46-0.960.810.770.77
-0.94-0.390.50.570.55-0.390.52-0.080.56-0.92-0.92-0.92-0.460.59-0.87-0.9-0.89
-0.82-0.930.980.980.98-0.930.99-0.310.99-0.85-0.85-0.85-0.960.59-0.91-0.88-0.81
0.980.76-0.85-0.88-0.870.76-0.860.23-0.890.990.990.990.81-0.87-0.911.00.94
0.990.72-0.81-0.85-0.840.72-0.830.21-0.861.01.01.00.77-0.9-0.881.00.95
0.940.72-0.76-0.8-0.790.72-0.780.17-0.80.950.950.950.77-0.89-0.810.940.95
Click cells to compare fundamentals

Pasithea Therapeutics Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Pasithea Therapeutics is a strong investment it is important to analyze Pasithea Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pasithea Therapeutics' future performance. For an informed investment choice regarding Pasithea Stock, refer to the following important reports:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Pasithea Therapeutics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pasithea Therapeutics. If investors know Pasithea will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pasithea Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(14.79)
Revenue Per Share
0.37
Quarterly Revenue Growth
14.981
Return On Assets
(0.38)
Return On Equity
(0.63)
The market value of Pasithea Therapeutics is measured differently than its book value, which is the value of Pasithea that is recorded on the company's balance sheet. Investors also form their own opinion of Pasithea Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Pasithea Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pasithea Therapeutics' market value can be influenced by many factors that don't directly affect Pasithea Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pasithea Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pasithea Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pasithea Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.